New Findings from Guangzhou University in Liver Diseases Provides New Insights (Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Liver Diseases have been published. According to news originating from Guangdong, People's Republic of China, by NewsRx correspondents, research stated, "Metabolizing and eliminating toxic chemicals in the liver are key processes in the body's defense system. Drug-metabolizing enzymes (DMEs) play central roles in such processes."
Our news journalists obtained a quote from the research from Guangzhou University, "The activity and expression of several key DMEs are changed in various liver diseases and thus lead to significantly altered drug disposition. This phenomenon severely affects the pharmacotherapy of clinical medications in terms of the safety and efficacy of drug responses. This review highlights liver physiological functions, altered DMEs, and altered drug disposition in liver diseases. Moreover, the implications of changes in DMEs on the fate of clinically relevant drugs are also discussed. Pregnane X receptor and constitutive androstane receptor are two liver-enriched nuclear receptors originally defined as xenobiotic sensors that affect regulation of DMEs. Altered regulation of DMEs in liver diseases contributes to the development of powerful in vitro and in vivo tools to predict drug responses and options for improved drug delivery and development. Although a number of treatment drugs are available for liver diseases, they are limited by their low drug concentration in the target site, presence of side effects, and instability in the human body. The nanoparticle drug delivery system has recently attracted research attention because of its potential to offer solutions to current obstacles that involve the use of therapeutic drugs for liver diseases."
According to the news editors, the research concluded: "Conclusively, this review aims to improve understanding on the regulation of DMEs in liver diseases and on corresponding implications in drug disposition, including novel therapeutic medications."
For more information on this research see: Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings. Current Medicinal Chemistry, 2014;21(22):2522-2541. Current Medicinal Chemistry can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Medicinal Chemistry - www.benthamscience.com/cmc/index.htm)
The news correspondents report that additional information may be obtained from L. Lu, Guangzhou Univ Chinese Med, Int Inst Translat Chinese Med, Guangzhou 510006, Guangdong, People's Republic of China. Additional authors for this research include J. Shi, Q. Li, X. Peng, L. Dong, Y. Li, P. Dai, Y. Wang, E. Guo, F. Zhou and Z. Liu (see also Liver Diseases).
Keywords for this news article include: Asia, Guangdong, Therapeutics, Liver Diseases, Enzymes and Coenzymes, Digestive System Diseases, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC